Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation

References

• Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:S73–S7.
   PubMedGoogle Scholar
• Commission of the European communities staff working document. Brussels: European Commission. 2008.
   Google Scholar
• Pontes H, Clement M, Rollason V. Safety signal detection: the relevance of literature review. Drug Saf. 2014;37:471–479.
   PubMed Web of Science ®Google Scholar
• Couzin J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004;306:384–385.
   PubMed Web of Science ®Google Scholar
• EMA European medicines agency recommends suspension of Avandia, Avandamet and Avaglim. London. 2010.
   Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. Jama. 2010;304:411–418.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191–1201.
   PubMed Web of Science ®Google Scholar
• European Parliament and Council. L 348/74 Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European medicines agency, and regulation (EC) No 1394/2007 on advanced therapy medicinal products. Off J Eur Union. 2010. L 348/74:1–16.
   Google Scholar
• Directive 192010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, directive 2001/83/EC on the community code relating to medicinal products for human use. Off J Eur Union. 2010. 74–99.
   Google Scholar
• European Medicines Agency. EMA questions and answers on the withdrawal of medicines containing benfluorex. London. 2010.
   Google Scholar
• Directive 192012/26/EU of the European Parliament and of the Council of 25 October 2012 amending directive 2001/83/EC as regards pharmacovigilance. Off J Eur Union. 2012. 1–4.
   Google Scholar
• Regulation (EU) No 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance. Off J Eur Union. 2012. 38–40.
   Google Scholar
• EMA. Pharmacovigilance legislation. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000491.jsp&mid=WC0b01ac058058f32d
   Google Scholar
• Calvo B, Zuniga L. EU’s new pharmacovigilance legislation: considerations for biosimilars. Drug Saf. 2014;37:9–18.
   PubMed Web of Science ®Google Scholar
• EMA. Implementation of the pharmacovigilance legislation. 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000520.jsp&mid=WC0b01ac05804fa031
   Google Scholar
• EMA one-year report on human medicines pharmacovigilance tasks of the European medicines agency. 2014.
   Google Scholar
• AIFA. Rete nazionale di farmacovigilanza. Rome: Italian Medicines Agency (AIFA). 2015.
   Google Scholar
• AIFA. Andamento delle segnalazioni di sospette reazioni avverse in Italia dal 2001 al 2013. 2014.
   Google Scholar
• Mazzitello C, Esposito S, De Francesco AE, et al. Pharmacovigilance in Italy: an overview. J Pharmacol Pharmacother. 2013;4:S20–S8.
   PubMedGoogle Scholar
• Pimpinella G, Tartaglia L. Pharmacovigilance and the italian medicines agency. J Pharmacol Pharmacother. 2013;4:S4–S6.
   PubMedGoogle Scholar
• AIFA. Fondi Regionali di Farmacovigilanza. 2014. Available from: http://www.agenziafarmaco.gov.it/it/content/fondi-regionali-di-farmacovigilanza-0
   Google Scholar
• Ministero dell Salute. Decreto 30 aprile 2015. Procedure operative e soluzioni tecniche per un’efficace azione di farmacovigilanza adottate ai sensi del comma 344 dell’articolo 1 della legge 24 dicembre 2012, n. 228 (Legge di stabilità 2013). 2015. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/DM_30_aprile 2015.pdf
   Google Scholar
• Giofre C, Scicchitano F, Palleria C, et al. Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis. J Pharmacol Pharmacother. L 0020. 2013;4:S55–S60.
   PubMedGoogle Scholar
• European Parliament and Council. Directive 192001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. 2001;34–44.
   Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), in Module VI – Management and reporting of adverse reactions to medicinal products (Rev 1). London. 2014.
   Google Scholar
• MedDRA. Medical dictionary for regulatory activities. McLean, USA: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 2015.
   Google Scholar
• ICH. MedDRA. [cited 2015 15 Oct]. Medical Dictionary for Regulatory Activities. 2015. Available from: http://www.ich.org/products/meddra.html
   Google Scholar
• WHO. Guidelines for ATC classification and DDD assignment 2016. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. 2015.
   Google Scholar
• Imamura S, Hirai K, Hirai A. The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients. Tohoku J Exp Med. 2013;231:57–61.
   PubMed Web of Science ®Google Scholar
• Scicchitano F, Giofre C, Palleria C, et al. Pharmacovigilance and drug safety 2011 in Calabria (Italy): adverse events analysis. J Res Med Sci. 2012;17:872–875.
   PubMed Web of Science ®Google Scholar
• EMA list of medicinal products under additional monitoring. 2015.
   Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004;329:15–19.
   PubMed Web of Science ®Google Scholar
• Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol. 2007;7:9.
   PubMedGoogle Scholar
• Franconi F, Campesi I, Occhioni S, et al. Sex and gender in adverse drug events, addiction, and placebo. Handb Exp Pharmacol. 2012;214:107–126.
   PubMedGoogle Scholar
• AIFA FAQ per la gestione delle segnalazioni nell’ambito della rete nazionale di farmacovigilanza. Aggiornamento Maggio. 2014;2014.
   Google Scholar
• Commission implementing Regulation (EU) No 198/2013 of 7 March 2013 on the selection of a symbol for the purpose of identifying medicinal products for human use that are subject to additional monitoring. Off J Eur Union. 2013. 17–18.
   Google Scholar
• AIFA. Medicinali sottoposti a monitoraggio addizionale. 2013. Available from: http://www.agenziafarmaco.gov.it/it/content/medicinali-sottoposti-monitoraggio-addizionale
   Google Scholar
• EMA. Medicines under additional monitoring. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000365.jsp&mid=WC0b01ac058067bfff
   Google Scholar
• AIFA. Andamento delle segnalazioni di sospette reazioni avverse in Italia (2001–2011). 2011. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/and_segn_2011_11052012def.pdf
   Google Scholar
• OSMED. L’uso dei farmaci in Italia: rapporto nazionale anno 2012. Rome: Il Pensiero Scientifico Editore; 2013.
   Google Scholar
• OSMED. L’uso dei farmaci in Italia: rapporto nazionale anno 2013. Rome: Il Pensiero Scientifico Editore; 2014.
   Google Scholar
• OSMED. L’uso dei farmaci in italia: rapporto nazionale anno 2014. Rome: Il Pensiero Scientifico Editore; 2015.
   Google Scholar
• OSMED. L’uso dei farmaci in Italia: rapporto nazionale anno 2011. Rome: Il Pensiero Scientifico Editore; 2012.
   Google Scholar
• Khazan M, Amouzegar A, Gharibzadeh S, et al. Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS). Horm Metab Res. 2014;46(13):980–984.
   Web of Science ®Google Scholar